These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34015579)

  • 1. Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity.
    Monahan DS; Flaherty E; Hameed A; Duffy GP
    Biomed Pharmacother; 2021 Aug; 140():111702. PubMed ID: 34015579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial resveratrol and quercetin polymeric micelles mitigate doxorubicin induced cardiotoxicity in vitro and in vivo.
    Cote B; Carlson LJ; Rao DA; Alani AWG
    J Control Release; 2015 Sep; 213():128-133. PubMed ID: 26160305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy.
    Szponar J; Ciechanski E; Ostrowska-Lesko M; Gorska A; Tchorz M; Dabrowska A; Dudka J; Murias M; Kowalczyk M; Korga-Plewko A; Mandziuk S
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of doxorubicin-induced cardiotoxicity in a human in vitro cardiac model by the induction of the NRF-2 pathway.
    Tomlinson L; Lu ZQ; Bentley RA; Colley HE; Murdoch C; Webb SD; Cross MJ; Copple IM; Sharma P
    Biomed Pharmacother; 2019 Apr; 112():108637. PubMed ID: 30798127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexrazoxane mitigates epirubicin-induced genotoxicity in mice bone marrow cells.
    Attia SM; Ahmad SF; Saquib Q; Harisa GI; Al-Khedhairy AA; Bakheet SA
    Mutagenesis; 2016 Mar; 31(2):137-45. PubMed ID: 26399706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracycline-Induced Atrial Structural and Electrical Remodeling Characterizes Early Cardiotoxicity and Contributes to Atrial Conductive Instability and Dysfunction.
    Tan R; Cong T; Xu G; Hao Z; Liao J; Xie Y; Lin Y; Yang X; Li Q; Liu Y; Xia YL
    Antioxid Redox Signal; 2022 Jul; 37(1-3):19-39. PubMed ID: 35081742
    [No Abstract]   [Full Text] [Related]  

  • 8. Chemotherapy-induced cardiotoxicity: a new perspective on the role of Digoxin, ATG7 activators, Resveratrol, and herbal drugs.
    Al-Hussaniy HA; Alburghaif AH; Alkhafaje Z; Al-Zobaidy MAJ; Alkuraishy HM; Mostafa-Hedeab G; Azam F; Al-Samydai AM; Al-Tameemi ZS; Naji MA
    J Med Life; 2023 Apr; 16(4):491-500. PubMed ID: 37305823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humanin analog enhances the protective effect of dexrazoxane against doxorubicin-induced cardiotoxicity.
    Lue Y; Gao C; Swerdloff R; Hoang J; Avetisyan R; Jia Y; Rao M; Ren S; Atienza V; Yu J; Zhang Y; Chen M; Song Y; Wang Y; Wang C
    Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H634-H643. PubMed ID: 29775411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
    Wu X; Hasinoff BB
    Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells.
    Smith TA; Phyu SM; Akabuogu EU
    Anticancer Res; 2016 Jan; 36(1):87-93. PubMed ID: 26722031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
    Kollárová-Brázdová P; Jirkovská A; Karabanovich G; Pokorná Z; Bavlovič Piskáčková H; Jirkovský E; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Skalická V; Štěrbová-Kovaříková P; Roh J; Šimůnek T; Štěrba M
    J Pharmacol Exp Ther; 2020 Jun; 373(3):402-415. PubMed ID: 32253261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
    Hasinoff BB; Patel D; Wu X
    Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
    Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
    J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.
    Wu V
    J Pediatr Oncol Nurs; 2015; 32(3):178-84. PubMed ID: 25366577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity.
    Liu H; Wang H; Xiang D; Guo W
    Mini Rev Med Chem; 2017; 17(1):44-50. PubMed ID: 27337969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.
    Reichardt P; Tabone MD; Mora J; Morland B; Jones RL
    Future Oncol; 2018 Oct; 14(25):2663-2676. PubMed ID: 29747541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.
    Spagnuolo RD; Recalcati S; Tacchini L; Cairo G
    Br J Pharmacol; 2011 May; 163(2):299-312. PubMed ID: 21232037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All-trans retinoic acid protects against doxorubicin-induced cardiotoxicity by activating the ERK2 signalling pathway.
    Yang L; Luo C; Chen C; Wang X; Shi W; Liu J
    Br J Pharmacol; 2016 Jan; 173(2):357-71. PubMed ID: 26507774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxymatrine Ameliorates Doxorubicin-Induced Cardiotoxicity in Rats.
    Zhang YY; Yi M; Huang YP
    Cell Physiol Biochem; 2017; 43(2):626-635. PubMed ID: 28946137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.